The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
María Díez-CampeloDuring the7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to María Díez Campelo, University Hospital of Salamanca, Salamanca, ES. We asked, What is new for MDS with del(5q)?
What is new for MDS with del(5q)?
In this video, Campelo discusses results from the interim analysis of the SINTRA-REV clinical trial (NCT01243476). The study confirmed that early treatment with low-dose lenalidomide delayed the time to and reduced the risk of transfusion dependency for patients with lower-risk, del(5q) MDS.